GlassScriptPhysician profile
William F Young
NPI 1982601787
$7,398.55
in general payments reported to CMS, 2019-2025
19 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $53.55 · 2021: $11.35 · 2022: $4,141 · 2023: $122 · 2024: $699 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Travel and Lodging: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.38 |
| Travel and Lodging | $1,398.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $3,302.27 | 2022 | |
| Insightec,INC | $3,283.82 | 2022-2025 | Exablate |
| Pfizer INC. | $203.48 | 2023-2025 | |
| Allergan, INC. | $156.71 | 2019 | |
| Abbvie INC. | $106.34 | 2022-2024 | |
| Medtronic USA, INC. | $69.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.56 | 2024 | Andexxa |
| Medtronic, INC. | $25.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.44 | 2020-2021 | |
| Aucta Pharmaceuticals, INC. | $23.90 | 2025 | Motpoly Xr |
| Depuy Synthes Sales INC. | $21.04 | 2019 | |
| Aquestive Therapeutics, INC. | $20.92 | 2020 | |
| Portola Pharmaceuticals, LLC | $19.54 | 2020 | |
| Adamas Pharmaceuticals, INC. | $18.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.72 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17.94 | 2023 | Tysabri, Vumerity |
| Servier Pharmaceuticals LLC | $17.11 | 2025 | |
| Sunovion Pharmaceuticals INC. | $14.58 | 2019 | |
| Ucb, INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.